Content area

Abstract

Background/Objectives: Glioblastoma (GBM), the most aggressive primary malignant brain tumor, has a dismal prognosis and limited treatment options. The dried rhizome of Ligusticum chuanxiong Hort. (Chuanxiong, CX) is a traditional Chinese medicinal herb frequently prescribed in formulas intended to invigorate blood circulation. CX also exhibits anti-glioma activity, but its molecular mechanisms remain incompletely understood. Methods: In this study, we combined transcriptomics and Raman spectroscopy to investigate the effects of reconstituted CX-dispensing granules (hereafter referred to as CXG solution) on U87MG cells, suggesting their dual role in promoting cell death and modulating collagen deposition and lipid metabolism. Results: Mechanistically, we demonstrated that the CXG solution downregulates hsa-miR-10a-5p, which directly targets BCL2L11, known to induce pro-apoptotic effects, as validated by qPCR and dual-luciferase reporter assays. Furthermore, the CXG solution and hsa-miR-10a-5p suppress lipid metabolism through a coherent feed-forward loop via targeting transcription factors SREBF1 and E2F1. An electrophoretic mobility shift assay (EMSA) confirmed E2F1 binds to the hsa-miR-29a promoter, leading to the synergistic repression of hsa-miR-29a-3p by SREBF1 and E2F1. Network pharmacology analysis combined with molecular docking suggested that the ferulic acid and adenosine in CX potentially modulate EGFR-the E2F1-hsa-miR-10a-5p axis. Conclusions: These findings elucidate CX’s multi-target anti-GBM mechanisms and propose a novel therapeutic strategy combining metabolic intervention with miRNA-targeted therapy, providing novel insights into feed-forward loop regulation in miRNA networks.

Details

1009240
Title
Ligusticum chuanxiong Hort. Targets hsa-miR-10a-5p to Potentially Induce Apoptosis and Modulate Lipid Metabolism in Glioblastoma: A Natural-Product-Based Therapeutic Strategy
Author
Xiao-Xuan, Cai 1   VIAFID ORCID Logo  ; Hua-Li, Zuo 1   VIAFID ORCID Logo  ; Li, Jing 1 ; Hsi-Yuan, Huang 1   VIAFID ORCID Logo  ; Li-Ping, Li 2 ; Ni Jie 2 ; Pei-Sen, Wu 3 ; Xiao-Yuan, Xu 3 ; Zhang, Dan 4 ; Yue-Yang, Xie 5 ; Huang Hsien-Da 6 ; Yang-Chi-Dung, Lin 1   VIAFID ORCID Logo 

 Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (X.-X.C.); [email protected] (H.-L.Z.); [email protected] (J.L.); [email protected] (H.-Y.H.); [email protected] (L.-P.L.); [email protected] (J.N.); [email protected] (Y.-Y.X.), School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (P.-S.W.); [email protected] (X.-Y.X.), Guangdong Provincial Key Laboratory of Digital Biology and Drug Development, The Chinese University of Hong Kong, Shenzhen 518172, China 
 Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (X.-X.C.); [email protected] (H.-L.Z.); [email protected] (J.L.); [email protected] (H.-Y.H.); [email protected] (L.-P.L.); [email protected] (J.N.); [email protected] (Y.-Y.X.), Guangdong Provincial Key Laboratory of Digital Biology and Drug Development, The Chinese University of Hong Kong, Shenzhen 518172, China 
 School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (P.-S.W.); [email protected] (X.-Y.X.) 
 Longgang Central Hospital of Shenzhen, Shenzhen 518116, China; [email protected] 
 Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (X.-X.C.); [email protected] (H.-L.Z.); [email protected] (J.L.); [email protected] (H.-Y.H.); [email protected] (L.-P.L.); [email protected] (J.N.); [email protected] (Y.-Y.X.), School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (P.-S.W.); [email protected] (X.-Y.X.) 
 Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (X.-X.C.); [email protected] (H.-L.Z.); [email protected] (J.L.); [email protected] (H.-Y.H.); [email protected] (L.-P.L.); [email protected] (J.N.); [email protected] (Y.-Y.X.), School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; [email protected] (P.-S.W.); [email protected] (X.-Y.X.), Guangdong Provincial Key Laboratory of Digital Biology and Drug Development, The Chinese University of Hong Kong, Shenzhen 518172, China, Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China 
Publication title
Volume
18
Issue
10
First page
1553
Number of pages
27
Publication year
2025
Publication date
2025
Publisher
MDPI AG
Place of publication
Basel
Country of publication
Switzerland
Publication subject
e-ISSN
14248247
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2025-10-15
Milestone dates
2025-06-25 (Received); 2025-10-13 (Accepted)
Publication history
 
 
   First posting date
15 Oct 2025
ProQuest document ID
3265930820
Document URL
https://www.proquest.com/scholarly-journals/i-ligusticum-chuanxiong-hort-targets-hsa-mir-10a/docview/3265930820/se-2?accountid=208611
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-10-28
Database
ProQuest One Academic